Risperidone long-acting injectable (Risperdal Consta^®) for maintenance treatment in patients with bipolar disorder

References

• Rihmer Z, Angst J. Mood Disorders: Epidemiology. Sadock BJ, Sadock VA, Ruiz P (Eds). Lippincott Williams & Wilkins, PA, USA, 1645–1652 (2009).
   Google Scholar
• Bauer M, Pfennig A. Epidemiology of bipolar disorders. Epilepsia46(Suppl. 4), 8–13 (2005).
   PubMed Web of Science ®Google Scholar
• Angst J, Gamma A, Lewinsohn P. The evolving epidemiology of bipolar disorder. World Psychiatry1, 146–148 (2002).
   PubMedGoogle Scholar
• Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 617–627 (2005).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Calabrese JR, Weissman MM et al. Screening for bipolar disorder in the community. J. Clin. Psychiatry64, 53–59 (2003).
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry59, 530–537 (2002).
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry60, 261–269 (2003).
   PubMed Web of Science ®Google Scholar
• Geller B, Tillman R, Craney JL, Bolhofner K. Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Arch. Gen. Psychiatry61, 459–467 (2004).
   PubMed Web of Science ®Google Scholar
• Birmaher B, Axelson D, Strober M et al. Clinical course of children and adolescents with bipolar spectrum disorders. Arch. Gen. Psychiatry63, 175–183 (2006).
   PubMed Web of Science ®Google Scholar
• Swann AC. Long-term treatment in bipolar disorder. J. Clin. Psychiatry66(Suppl. 1), 7–12 (2005).
   PubMedGoogle Scholar
• Suppes T, Dennehy EB, Hirschfeld RM et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry66, 870–886 (2005).
   PubMed Web of Science ®Google Scholar
• Keck PE, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder 2004. Postgraduate Medicine Special Report, 1–120 (2004).
   Google Scholar
• Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 11, 225–255 (2009).
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (Revision). Am. J. Psychiatry159, 1–50 (2002).
   Web of Science ®Google Scholar
• Tohen M, Zarate CA Jr, Hennen J et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am. J. Psychiatry160, 2099–2107 (2003).
   PubMed Web of Science ®Google Scholar
• Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am. J. Psychiatry152, 1635–1640 (1995).
   PubMed Web of Science ®Google Scholar
• Coryell W, Turvey C, Endicott J et al. Bipolar I affective disorder: predictors of outcome after 15 years. J. Affect. Disord.50, 109–116 (1998).
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Harrow M. Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up. J. Affect. Disord.81, 123–131 (2004).
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Hennen J, Baldessarini RJ et al. Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disord.7, 68–76 (2005).
   PubMed Web of Science ®Google Scholar
• Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr. Scand.105, 164–172 (2002).
   PubMed Web of Science ®Google Scholar
• Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J. Clin. Psychiatry63, 384–390 (2002).
   PubMed Web of Science ®Google Scholar
• Rosa AR, Marco M, Fachel JM, Kapczinski F, Stein AT, Barros HM. Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients. Prog. Neuropsychopharmacol. Biol. Psychiatry31, 217–224 (2007).
   PubMed Web of Science ®Google Scholar
• Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am. J. Psychiatry159, 1927–1929 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am. J. Psychiatry153, 993–1000 (1996).
   PubMed Web of Science ®Google Scholar
• Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch. Gen. Psychiatry48, 1082–1088 (1991).
   PubMed Web of Science ®Google Scholar
• Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr. Serv.52, 805–811 (2001).
   PubMed Web of Science ®Google Scholar
• Lew KH, Chang EY, Rajagopalan K, Knoth RL. The effect of medication adherence on health care utilization in bipolar disorder. Manag. Care Interface19, 41–46 (2006).
   PubMedGoogle Scholar
• Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs21, 441–448 (2007).
   PubMed Web of Science ®Google Scholar
• McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J. Clin. Psychiatry67(Suppl. 5), 15–18 (2006).
   PubMed Web of Science ®Google Scholar
• Dencker SJ, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs6, 367–381 (1996).
   Web of Science ®Google Scholar
• Manji HK, Lenox RH. The nature of bipolar disorder. J. Clin. Psychiatry61(Suppl. 13), 42–57 (2000).
   PubMed Web of Science ®Google Scholar
• Martinowich K, Schloesser RJ, Manji HK. Bipolar disorder: from genes to behavior pathways. J. Clin. Invest.119, 726–736 (2009).
   PubMedGoogle Scholar
• Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA Jr. The neurobiology of the switch process in bipolar disorder: a review. J. Clin. Psychiatry DOI: 10.4088/JCP.09r05259gre (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Craig TJ, Grossman S, Mojtabai R et al. Medication use patterns and 2-year outcome in first-admission bipolar disorder with psychotic features. Bipolar Disord.6, 406–415 (2004).
   PubMed Web of Science ®Google Scholar
• Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr. Serv.59, 1175–1183 (2008).
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord.5, 421–433 (2003).
   PubMed Web of Science ®Google Scholar
• Grunze HC. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr.13, 790–795 (2008).
   PubMedGoogle Scholar
• Post RM, Leverich GS, Nolen WA et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord.5, 396–406 (2003).
   PubMed Web of Science ®Google Scholar
• Sachs GS, Nierenberg AA, Calabrese JR et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med.356, 1711–1722 (2007).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA271, 918–924 (1994).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry66, 111–121 (2005).
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Garno JL, Harrow M. Long-term remission and recovery in bipolar disorder: a review. Curr. Psychiatry Rep.7, 456–461 (2005).
   PubMedGoogle Scholar
• Ghaemi SN, Hsu DJ, Thase ME et al. Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. Psychiatr. Serv.57, 660–665 (2006).
   PubMed Web of Science ®Google Scholar
• Ketter TA, Wang PW, Nowakowska C, Marsh WK, Bonner J. Treatment of acute mania in bipolar disorder. In: Advances in Treatment of Bipolar Disorder. Ketter TA (Ed.). American Psychiatric Publishing, Washington, DC, USA, 11–55 (2005).
   Google Scholar
• Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br. J. Psychiatry182, 141–147 (2003).
   PubMed Web of Science ®Google Scholar
• Tohen M, Bowden CL, Smulevich AB et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br. J. Psychiatry192, 135–143 (2008).
   PubMed Web of Science ®Google Scholar
• Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J. Clin. Psychopharmacol.24, 599–606 (2004).
   PubMed Web of Science ®Google Scholar
• Vieta E, T’joen C, McQuade RD et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am. J. Psychiatry165, 1316–1325 (2008).
   PubMed Web of Science ®Google Scholar
• Prien RF, Caffey EM Jr, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch. Gen. Psychiatry26, 146–153 (1972).
   PubMed Web of Science ®Google Scholar
• Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch. Gen. Psychiatry32, 34–42 (1975).
   PubMed Web of Science ®Google Scholar
• Cookson J, Silverstone T, Wells B. Double-blind comparative clinical trial of pimozide and chlorpromazine in mania. A test of the dopamine hypothesis. Acta Psychiatr. Scand.64, 381–397 (1981).
   PubMedGoogle Scholar
• Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin. Neuropharmacol.21, 176–180 (1998).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J. Clin. Psychiatry57, 142–146 (1996).
   PubMed Web of Science ®Google Scholar
• Chou JC, Czobor P, Charles O et al. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. J. Clin. Psychopharmacol.19, 500–505 (1999).
   PubMed Web of Science ®Google Scholar
• Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch. Gen. Psychiatry60, 1218–1226 (2003).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania – a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur. Neuropsychopharmacol.15, 573–585 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br. J. Psychiatry52(Suppl.), S13–S19 (2009).
   Google Scholar
• Ahlfors UG, Baastrup PC, Dencker SJ et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr. Scand.64, 226–237 (1981).
   PubMed Web of Science ®Google Scholar
• Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br. J. Psychiatry148, 723–725 (1986).
   PubMed Web of Science ®Google Scholar
• Bond DJ, Pratoomsri W, Yatham LN. Depot antipsychotic medications in bipolar disorder: a review of the literature. Acta Psychiatr. Scand. (Suppl. 434), 3–16 (2007).
   Google Scholar
• White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int. Clin. Psychopharmacol.8, 119–122 (1993).
   PubMed Web of Science ®Google Scholar
• Cavazzoni PA, Berg PH, Kryzhanovskaya LA et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J. Clin. Psychiatry67, 107–113 (2006).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J. Clin. Psychiatry61(Suppl. 4), 33–38 (2000).
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J. Clin. Psychopharmacol.28, 203–209 (2008).
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Litman RE, Pickar D. Adverse effects of antipsychotic drugs. Drug Saf.9, 429–436 (1993).
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry161, 414–425 (2004).
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry60, 553–564 (2003).
   PubMed Web of Science ®Google Scholar
• Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf.22, 195–214 (2000).
   PubMed Web of Science ®Google Scholar
• Package insert. Risperdal Consta (risperidone) long-acting injection: US prescribing information. Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ, USA (2010).
   Google Scholar
• Gefvert O, Eriksson B, Persson P et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int. J. Neuropsychopharmacol.8, 27–36 (2005).
   PubMed Web of Science ®Google Scholar
• Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann. Pharmacother.38, 2122–2127 (2004).
   PubMed Web of Science ®Google Scholar
• van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch .Int. Pharmacodyn. Ther.160, 492–494 (1966).
   PubMedGoogle Scholar
• Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science188, 1217–1219 (1975).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull.2, 19–76 (1976).
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol.7(Suppl. 1), S1–S5 (2004).
   PubMedGoogle Scholar
• Bobo WV, Rapoport J, Abi-Dargham A, Meltzer HY. The neurobiology of schizophrenia. In: Psychiatry. Third Edition. Tasman A, Maj M, First MB, Kay J, Lieberman JA (Eds). John Wiley & Sons Inc, NH, USA, 301–316 (2008).
   Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci.68, 29–39 (2000).
   PubMed Web of Science ®Google Scholar
• Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry60(Suppl. 10), 5–14 (1999).
   PubMed Web of Science ®Google Scholar
• Cosi C, Carilla-Durand E, Assie MB et al. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur. J. Pharmacol.535, 135–144 (2006).
   PubMedGoogle Scholar
• Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther.302, 381–389 (2002).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther.251, 238–246 (1989).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull.25, 390–392 (1989).
   PubMed Web of Science ®Google Scholar
• Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.)124, 57–73 (1996).
   PubMed Web of Science ®Google Scholar
• Eerdekens M, Van Hore I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res.70, 91–100 (2004).
   PubMed Web of Science ®Google Scholar
• Ramstack M, Grandolfi GP, Mannaert E, D’Hoore P, Lasser RA. Long-acting risperidone: prolonged-release injectable delivery of risperidone using Medisorb microsphere technology. Schizophr. Res.60, 314 (2010).
   Google Scholar
• Thyssen A, Rusch S, Herben V, Quiroz J, Mannaert E. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J. Clin. Pharmacol.50(9), 1011–1021 (2010).
   PubMed Web of Science ®Google Scholar
• Heykants J, Huang ML, Mannens G et al. The pharmacokinetics of risperidone in humans: a summary. J. Clin. Psychiatry55(Suppl.), 13–17 (1994).
   PubMed Web of Science ®Google Scholar
• Berecz R, Dorado P, de la RA, Caceres MC, Degrell I, LLerena A. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Curr. Drug Targets5, 573–579 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet.48, 689–723 (2009).
   PubMed Web of Science ®Google Scholar
• Package insert. Risperdal (risperidone): US prescribing information. (2010). Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Titusville, NJ, USA.
   Google Scholar
• Elliott HL, Sumner DJ, McLean K, Reid JL. Effect of age on the responsiveness of vascular a-adrenoceptors in man. J. Cardiovasc. Pharmacol.4, 388–392 (1982).
   PubMedGoogle Scholar
• Andros E, Detmar-Hanna D, Suteparuk S, Gal J, Gerber JG. The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Eur. J. Clin. Pharmacol.50, 41–46 (1996).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann. Neurol.44, 143–147 (1998).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Gur RC, Wang GJ et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am. J. Psychiatry155, 344–349 (1998).
   PubMed Web of Science ®Google Scholar
• Antonini A, Leenders KL, Reist H, Thomann R, Beer HF, Locher J. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. Arch. Neurol.50, 474–480 (1993).
   PubMedGoogle Scholar
• Woolcott JC, Richardson KJ, Wiens MO et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch. Intern. Med.169, 1952–1960 (2009).
   PubMedGoogle Scholar
• Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J. Clin. Psychopharmacol.19, 322–328 (1999).
   PubMed Web of Science ®Google Scholar
• Hoffman WF, Labs SM, Casey DE. Neuroleptic-induced parkinsonism in older schizophrenics. Biol. Psychiatry22, 427–439 (1987).
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA294, 1934–1943 (2005).
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Scordo MG et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J. Clin. Psychopharmacol.22, 419–423 (2002).
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Newcomer JW, Jackson K et al. Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. Psychopharmacology (Berl.)116, 291–296 (1994).
   PubMedGoogle Scholar
• Spina E, Avenoso A, Facciola G et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther. Drug Monit.22, 481–485 (2000).
   PubMed Web of Science ®Google Scholar
• Bork JA, Rogers T, Wedlund PJ, de Lean J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J. Clin. Psychiatry60, 469–476 (1999).
   PubMed Web of Science ®Google Scholar
• Dunner DL. Drug interactions of lithium and other antimanic/mood-stabilizing medications. J. Clin. Psychiatry64(Suppl. 5), 38–43 (2003).
   PubMedGoogle Scholar
• Spina E, D’Arrigo C, Migliardi G et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther. Drug Monit.28, 599–602 (2006).
   PubMed Web of Science ®Google Scholar
• Rosaria MM, Pacetti M, Cacciola M et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia46, 771–774 (2005).
   PubMedGoogle Scholar
• Savas HA, Yumru M, Ozen ME. Use of long-acting risperidone in the treatment of bipolar patients. J. Clin. Psychopharmacol.26, 530–531 (2006).
   PubMed Web of Science ®Google Scholar
• Bech P, Bolwig TG, Dein E, Jacobsen O, Gram LF. Quantitative rating of manic states. Correlation between clinical assessment and Biegel’s Objective Rating Scale. Acta Psychiatr. Scand.52, 1–6 (1975).
   PubMed Web of Science ®Google Scholar
• Han C, Lee MS, Pae CU, Ko YH, Patkar AA, Jung IK. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry31, 1219–1223 (2007).
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry133, 429–435 (1978).
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol. Rep.10, 799–812 (1962).
   Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry23, 56–62 (1960).
   PubMed Web of Science ®Google Scholar
• Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ No ADM 76–338). National Institute of Mental Health, MD, USA, 218–222 (1976).
   Google Scholar
• Braunig P, Sacchetti E, Medori R. Risperidone long-acting injectable for maintenance therapy in bipolar disorder: an open-label pilot study. Int. J. Psychiatry Clin. Pract.12, 74–77 (2008).
   PubMed Web of Science ®Google Scholar
• Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int. Clin. Psychopharmacol.20, 121–130 (2005).
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull.13, 261–276 (1987).
   PubMed Web of Science ®Google Scholar
• Startup M, Jackson MC, Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br. J. Clin. Psychol.41, 417–422 (2002).
   PubMed Web of Science ®Google Scholar
• Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. Int. Clin. Psychopharmacol.23, 88–94 (2008).
   PubMed Web of Science ®Google Scholar
• Vieta E, Nieto E, Autet A et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J. Biol. Psychiatry9, 219–224 (2008).
   PubMed Web of Science ®Google Scholar
• Benabarre A, Castro P, Sanchez-Moreno J et al. [Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder]. Actas Esp. Psiquiatr.37, 143–147 (2009).
   PubMed Web of Science ®Google Scholar
• Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr. Scand. Suppl., 50–56 (2007).
   Google Scholar
• Macfadden W, Alphs L, Haskins JT et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 11, 827–839 (2009).
   Google Scholar
• Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol. Psychiatry68, 156–162 (2010).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry134, 382–389 (1979).
   PubMed Web of Science ®Google Scholar
• Hamilton M. Hamilton Anxiety Scale. In: ECDEU Assessment Manual for Psychopharmacology. Guy W (Ed.). Department of Health, Education and Welfare, MD, USA, 193–198 (1976).
   Google Scholar
• EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy16, 199–208 (1990).
   PubMed Web of Science ®Google Scholar
• Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res.73, 159–171 (1997).
   PubMed Web of Science ®Google Scholar
• Peselow ED, Dunner DL, Fieve RR, Lautin A. Lithium carbonate and weight gain. J. Affect. Disord.2, 303–310 (1980).
   PubMed Web of Science ®Google Scholar
• Ness-Abramof R, Apovian CM. Drug-induced weight gain. Timely Top. Med. Cardiovasc. Dis.9, E31 (2005).
   Google Scholar
• Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf.24, 969–978 (2001).
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Thieda P, Hansen RA et al. Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis. Drug Saf.31, 851–865 (2008).
   PubMed Web of Science ®Google Scholar
• Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J. Nerv. Ment. Dis.173, 353–357 (1985).
   PubMed Web of Science ®Google Scholar
• Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry154, 672–676 (1989).
   PubMed Web of Science ®Google Scholar
• Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl.212, 11–19 (1970).
   PubMedGoogle Scholar
• Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs64, 2291–2314 (2004).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Nuamah IF et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J. Clin. Psychiatry69, 817–829 (2008).
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Czobor P, Alphs L et al. The InterSePT scale for suicidal thinking reliability and validity. Schizophr. Res.63, 161–170 (2003).
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int. J. Neuropsychopharmacol.11, 999–1029 (2008).
   PubMedGoogle Scholar
• Berk L, Hallam KT, Colom F et al. Enhancing medication adherence in patients with bipolar disorder. Hum. Psychopharmacol.25, 1–16 (2010).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, McElroy SL, Strakowski SM et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am. J. Psychiatry155, 646–652 (1998).
   PubMed Web of Science ®Google Scholar
• Strakowski SM, Keck PE Jr, McElroy SL et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch. Gen. Psychiatry55, 49–55 (1998).
   PubMed Web of Science ®Google Scholar
• Velligan DI, Wang M, Diamond P et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr. Serv.58, 1187–1192 (2007).
   PubMed Web of Science ®Google Scholar
• Byerly M, Fisher R, Whatley K et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res.133, 129–133 (2005).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Vieta E, El-Mallakh R et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol. Psychiatry56, 957–963 (2004).
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Ostacher MJ, Calabrese JR et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am. J. Psychiatry163, 210–216 (2006).
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Sachs GS. Long-term risperidone treatment in bipolar disorder: 6-month follow up. Int. Clin. Psychopharmacol.12, 333–338 (1997).
   PubMed Web of Science ®Google Scholar
• Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J. Affect. Disord.50, 143–151 (1998).
   PubMed Web of Science ®Google Scholar
• Vieta E, Gasto C, Otero A, Nieto E, Vallejo J. Differential features between bipolar I and bipolar II disorder. Compr. Psychiatry38, 98–101 (1997).
   PubMed Web of Science ®Google Scholar
• Benazzi F. Bipolar II disorder : epidemiology, diagnosis and management. CNS Drugs21, 727–740 (2007).
   PubMed Web of Science ®Google Scholar
• Grant BF, Stinson FS, Hasin DS et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry66, 1205–1215 (2005).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Altshuler LL, Suppes T et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am. J. Psychiatry158, 420–426 (2001).
   PubMed Web of Science ®Google Scholar
• Feinman JA, Dunner DL. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J. Affect. Disord.37, 43–49 (1996).
   PubMed Web of Science ®Google Scholar
• Mazza M, Mandelli L, Di Nicola M et al. Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. J. Affect. Disord.115, 27–35 (2009).
   PubMed Web of Science ®Google Scholar
• Dalton EJ, Cate-Carter TD, Mundo E, Parikh SV, Kennedy JL. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord.5, 58–61 (2003).
   PubMed Web of Science ®Google Scholar
• Turkington A, Mulholland CC, Rushe TM et al. Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br. J. Psychiatry195, 242–248 (2009).
   PubMed Web of Science ®Google Scholar
• Perlis RH, Ostacher MJ, Miklowitz DJ et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J. Clin. Psychiatry71, 296–303 (2010).
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord.8, 232–241 (2006).
   PubMed Web of Science ®Google Scholar
• Manwani SG, Szilagyi KA, Zablotsky B, Hennen J, Griffin ML, Weiss RD. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. J. Clin. Psychiatry68, 1172–1176 (2007).
   PubMed Web of Science ®Google Scholar
• Lee S, Tsang A, Kessler RC et al. Rapid-cycling bipolar disorder: cross-national community study. Br. J. Psychiatry196, 217–225 (2010).
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Akiskal HS, Angst J et al. Bipolar disorder with frequent mood episodes in the national comorbidity survey replication (NCS-R). Mol. Psychiatry DOI: 10.1038/mp.2009.61 (2009) (Epub ahead of print).
   Google Scholar
• Sharma R, Markar HR. Mortality in affective disorder. J. Affect. Disord. 31, 91–96 (1994).
   Google Scholar
• Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? Curr. Psychiatry Rep.11, 475–480 (2009).
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J. Clin. Psychiatry67, e16 (2006).
   PubMed Web of Science ®Google Scholar
• Birkenaes AB, Opjordsmoen S, Brunborg C et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J. Clin. Psychiatry68, 917–923 (2007).
   PubMed Web of Science ®Google Scholar
• Glazer WM. The depot paradox. Behav. Healthc.27, 44–46 (2007).
   PubMedGoogle Scholar
• Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J. Clin. Psychiatry70, 196–200 (2009).
   PubMed Web of Science ®Google Scholar
• Heres S, Hamann J, Kissling W, Leucht S. Attitudes of psychiatrists toward antipsychotic depot medication. J. Clin. Psychiatry67, 1948–1953 (2006).
   PubMed Web of Science ®Google Scholar
• Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res.175, 58–62 (2010).
   PubMed Web of Science ®Google Scholar
• Patel MX, Nikolaou V, David AS. Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol. Med.33, 83–89 (2003).
   PubMed Web of Science ®Google Scholar